The general-purpose video visit, the emblem of pandemic-era health care, has settled into a modest permanent role: useful for triage, prescriptions and follow-ups, and unremarkable for everything else.

The growth has moved elsewhere. The telehealth companies expanding this year are narrow by design, built around a single condition, a defined protocol and a relationship measured in months rather than minutes: hormone optimization, weight management, dermatology, behavioral health, men's and women's health clinics that combine diagnostics, prescriptions and recurring clinical check-ins.

Why narrow works

The economics differ fundamentally from the visit-based model. A general telehealth platform sells appointments and competes on convenience. A condition-specific clinic sells outcomes over time and earns recurring revenue that looks more like a subscription business than a medical practice.

The clinical logic follows the same shape. Chronic and lifestyle conditions are managed, not cured, and management is mostly communication: lab review, dosage adjustment, adherence support. Those are tasks video and messaging handle well, arguably better than episodic in-person visits ever did.

The regulatory watch

The model's growth has drawn scrutiny proportional to its marketing. State boards continue to tighten rules around asynchronous prescribing, and operators that invested early in genuine clinical infrastructure, licensed providers, real lab relationships, conservative protocols, are increasingly separating from those that treated medicine as a checkout flow.

The second act of telehealth, in other words, looks less like an app and more like a clinic that happens to have no waiting room.

That shift follows earlier coverage of Repairable Tech Goes Mainstream, and Profitable.

Topics health caretechnology